Real-world data link semaglutide, tirzepatide to improved heart failure outcomes Semaglutide and tirzepatide can help patients with heart failure with preserved ejection fraction (HFpEF) significantly improve their heart health, according to new data presented at ESC Congress 2025, the annual meeting of the European Society of Cardiology
Key Takeaways Side effects are predictable, dose-dependent, and time-limited for most patients Nausea typically peaks within 48 weeks and improves with body adaptation Each dose escalation produces a temporary, milder return of symptoms Weeks 26 are when most patients quit this is the wrong time to stop Protein, hydration, and resistance training prevent the most common long-term issues (muscle loss, fatigue, constipation) Serious side effects are uncommon but recognisable knowing the warning signs matters If symptoms are unmanageable, ask your prescriber to delay (not skip) a dose escalation References Hawkins-Jarrett ZC, PharmD
With semaglutide, people typically start at a low dose and increase slowly over time
There is no need for a waiting period
For weight loss, its most famously known as Wegovy
Laboratory/In-Vitro Experimental Use Only.
&srotate=0)
